Literature DB >> 19262723

When is a line not a line?

Howard S Hochster1.   

Abstract

Year:  2007        PMID： 19262723      PMCID： PMC2632875     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  7 in total

1.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

Authors:  A de Gramont; J Vignoud; C Tournigand; C Louvet; T André; C Varette; E Raymond; S Moreau; N Le Bail; M Krulik
Journal:  Eur J Cancer       Date:  1997-02       Impact factor: 9.162

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

4.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Authors:  Mace L Rothenberg; Amit M Oza; Robert H Bigelow; Jordan D Berlin; John L Marshall; Ramesh K Ramanathan; Lowell L Hart; Sunil Gupta; Carlos A Garay; Brent G Burger; Nathalie Le Bail; Daniel G Haller
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

5.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Authors:  Axel Grothey; Daniel Sargent; Richard M Goldberg; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Second-line therapy for advanced colorectal cancer.

Authors:  Alessandra P Guglielmi; Alberto F Sobrero
Journal:  Gastrointest Cancer Res       Date:  2007-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.